Key facts
- GC Therapeutics’s last known valuation is $135.0M.
- It has raised $74.7M; the latest was Later Stage VC ($65.0M) in Sep 2024.
- Notable investors include Alumni Ventures, Andreessen Horowitz, Global Brain, Gaingels, Calm Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for GC Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for GC Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GC Therapeutics
Developer of a genome-wide cell programming platform designed to convert patient-derived stem cells into multiple cell types. The company integrates synthetic biology, artificial intelligence, and proprietary differentiation technology to create cell therapies with streamlined manufacturing and improved quality, enabling healthcare professionals to access advanced cell therapy options for patient care.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 42
- Website
- gc-tx.com/
- Ownership
- Privately Held (backing)
GC Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GC Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GC Therapeutics in its N-PORT filings yet. We sweep new filings monthly.